Drug
Eicosapentaenoic acid ethyl ester clinical trials
Also written Vascepa, Icosapent ethyl and AMR101.
- studies test it
- 31
- open now
- 3
- in phase 3
- 13
- first study started
- 1996
Keep track of what changes. Save the eicosapentaenoic acid ethyl ester studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2020 (6)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 2001 | 3 |
| 2004 | 1 |
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 9
- Phase 3
- 13
- Phase 4
- 9
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 25
Amarin Pharma Inc. (3) · Massachusetts General Hospital (2) · Canadian Medical and Surgical Knowledge Translation Research Group (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Mark A Hull, PhD FRCP (1) · Wihuri Research Institute (1) · VA Office of Research and Development (1) · Mochida Pharmaceutical Company, Ltd. (1)
Often tested with
Tested in the same studies.
Dasatinib (1) · Eicosapentaenoic Acid (1) · Bempedoic Acid/Ezetimibe (1) · Inclisiran (1) · Empagliflozin (1) · Colchicine (1)
Studies
Open first, then newest update. How each study uses eicosapentaenoic acid ethyl ester is read from its arms, and is right about nine times in ten.
Testing it · 31
- Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTNot yet recruitingPhase 4China National Center for Cardiovascular DiseasesNCT07762755Written as icosapent ethyl (IPE)
- Targeting Vascular INflammation in Patients With Community-Acquired PneumoniaRecruitingPhase 3Ottawa Heart Institute Research CorporationNCT06710080Written as Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
- Effect of Icosapent-ethyl Ester (IPE) to Reduce the Residual Risk Cardiovascular Disease.Not yet recruitingNot applicableUniversity of Sao PauloNCT06720662Written as Icosapent-ethyl ester capsules
- IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssionActive, not recruitingPhase 2Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT06466278Written as Icosapent ethyl
- Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the BodyTerminatedPhase 1/2National Cancer Institute (NCI)NCT05198843Written as Icosapent Ethyl
- The Effect of E-EPA on Circulating LDL and Plasma Lipid MetabolismCompletedNot applicableWihuri Research InstituteNCT04152291Written as Ethyl-Eicosapentaenoic Acid (E-EPA)
- EPA for Metastasis Trial 2Active, not recruitingPhase 3Mark A Hull, PhD FRCPNCT03428477Written as Icosapent Ethyl
- Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)WithdrawnPhase 4University of LouisvilleNCT06280976Written as Vascepa
- Brain Amyloid and Vascular Effects of Eicosapentaenoic AcidCompletedPhase 2/3VA Office of Research and DevelopmentNCT02719327Written as icosapent ethyl (IPE)
- Efficacy of Ethyl Icosapentate in Patients With Severe HypertriglyceridemiaCompletedPhase 3Mochida Pharmaceutical Company, Ltd.NCT04239950Written as Ethyl Icosapentate
- PRevention Using EPA Against coloREctal CancerCompletedPhase 1/2Massachusetts General HospitalNCT04216251Written as AMR101
- The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular RiskCompletedPhase 4Canadian Medical and Surgical Knowledge Translation Research GroupNCT04562467Written as Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
- A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk AdultsTerminatedPhase 4Kaiser PermanenteNCT04505098Written as Icosapent ethyl
- Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin TherapyCompletedPhase 4Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterNCT02926027Written as Vascepa
- A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic AcidWithdrawnPhase 4New York State Psychiatric InstituteNCT04811404Written as Ethyl Eicosapentaenoic Acid
- Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)CompletedPhase 3Amarin Pharma Inc.NCT01047501Written as AMR101 (ethyl icosapentate) - 4 g/day
- Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dLCompletedPhase 3Amarin Pharma Inc.NCT01047683Written as AMR101 (ethyl icosapentate) - 4 g/day
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on StatinCompletedPhase 3Amarin Pharma Inc.NCT01492361Written as AMR101
- Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic SubjectsTerminatedPhase 3Brigham and Women's HospitalNCT02422446Written as Icosapent ethyl
- An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19CompletedPhase 2Canadian Medical and Surgical Knowledge Translation Research GroupNCT04412018Written as Icosapent ethyl
See all 31 studies that test eicosapentaenoic acid ethyl ester →
Given in every arm · 2 — eicosapentaenoic acid ethyl ester is usual care beside what is tested
- A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe HypertriglyceridemiaNot yet recruitingPhase 3Zhejiang Doer Biologics Co., Ltd.NCT07680829Written as Icosapent Ethyl Oral Capsule
- PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPACompletedPhase 1Thetis Pharmaceuticals LLCNCT02113163Written as Metformin HCl and Vascepa
As the comparator · 3 — what is tested is compared with eicosapentaenoic acid ethyl ester
- CreNeuroS™️CNS Fish Oil Plus Softgels Compared to Vascepa® Capsules and Deplin® Capsules in a Pharmacokinetic, Single Dose Evaluation on Healthy Adult Human Subjects Under Fasting ConditionsEnrolling by invitationNot applicableSichuan Credit Pharmaceutical Co., Ltd.NCT06758778Written as Vascepa® (Icosapent ethyl) 1000 mg Capsules, Deplin® (L-methylfolate Calcium) 7.5 mg Capsules
- Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With HypertriglyceridemiaCompletedPhase 2Matinas BioPharma Nanotechnologies, Inc.NCT04177680Written as icosapent ethyl
- Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)CompletedPhase 1AstraZenecaNCT02859129Written as Multiple (20) oral doses of 2 g Vascepa® every 12 hours
Codes
What other systems call eicosapentaenoic acid ethyl ester · ClinicalTrials.gg INT003046
- MeSH (NLM) C035276eicosapentaenoic acid ethyl esterConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6GC8A4PAYHICOSAPENT ETHYLConfirmed FDA, NLM
- RxNorm 1304974One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C035276 | eicosapentaenoic acid ethyl ester | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6GC8A4PAYH | ICOSAPENT ETHYL | Confirmed FDA, NLM |
| RxNorm | 1304974 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.